SCHEMBL2270229

SCHEMBL2270229

O=CN1CCCN(CCC2CCN(c3ncc(Cl)cc3NC(=O)c3cccc(Cl)c3)CC2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 2/20 0.63
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CACNA1I Q9P0X4 2/20 0.42
KCNH2 Q12809 1/20 0.42
DRD2 P14416 4/20 0.40
POLB P06746 2/20 0.40
DRD3 P35462 2/20 0.40
AURKA O14965 1/20 0.39
JAK2 O60674 1/20 0.39
JAK3 P52333 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HTR1A P08908 1/20 0.39
HTR2A P28223 1/20 0.39
HTR7 P34969 1/20 0.39
HTR6 P50406 1/20 0.39
LMNA P02545 2/20 0.38
USP2 O75604 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2267308 0.91 CXCR3 (0.70) CXCR3MEN1KMT2ACACNA1IKCNH2
SCHEMBL2268257 0.91 CXCR3 (0.70) CXCR3MEN1KMT2ACACNA1IKCNH2
SCHEMBL2272173 0.90 CXCR3 (0.65) CXCR3MEN1KMT2ACACNA1IKCNH2
SCHEMBL2269089 0.88 CXCR3 (0.69) CXCR3MEN1KMT2ACACNA1IKCNH2
SCHEMBL2271450 0.87 CXCR3 (0.69) CXCR3MEN1KMT2ACACNA1IKCNH2
SCHEMBL2279434 0.86 CXCR3 (0.64) CXCR3MEN1KMT2ACACNA1IKCNH2
SCHEMBL2279689 0.86 CXCR3 (0.65) CXCR3MEN1KMT2ACACNA1IKCNH2
SCHEMBL2223061 0.86 CXCR3 (0.68) CXCR3MEN1KMT2ACACNA1IKCNH2
SCHEMBL2221700 0.86 CXCR3 (0.68) CXCR3MEN1KMT2ACACNA1IKCNH2
SCHEMBL12515715 0.85 CXCR3 (0.67) CXCR3MEN1KMT2ACACNA1IKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US claimed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO claimed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-8952004-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2015-02-10 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-31 US disclosed
WO-2011084985-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029971-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 CXCR3 1/4885MEN1 3640/4885KMT2A 3936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.